Get the Stockscreener App
17.72
1.08%
0.1907
Phathom Pharmaceuticals Inc stock is traded at $17.72, with a volume of 131.02K.
It is up +1.08% in the last 24 hours and up +18.13% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$17.53
Open:
$17.9
24h Volume:
131.02K
Relative Volume:
0.12
Market Cap:
$1.26B
Revenue:
$114.04M
Net Income/Loss:
$-330.15M
P/E Ratio:
-3.7464
EPS:
-4.73
Net Cash Flow:
$-274.85M
1W Performance:
+20.63%
1M Performance:
+18.13%
6M Performance:
+70.06%
1Y Performance:
+137.85%
1-Day Range:
$17.29
$17.90
1-Week Range:
$14.53
$17.90
52-Week Range:
$2.21
$17.90
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
17.71 | 1.25B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.45 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.23 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
411.19 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
856.37 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.91 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Raymond James | Strong Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals stock hits 52-week high at $17.87 - Investing.com
Bull Run: Why Phathom Pharmaceuticals Inc. stock is favored by pension funds2025 Winners & Losers & Weekly Stock Performance Updates - Улправда
Is Phathom Pharmaceuticals Inc. stock cheap at current valuationWeekly Profit Report & Daily Profit Maximizing Tips - DonanımHaber
Will Phathom Pharmaceuticals Inc. stock benefit from AI adoptionBear Alert & Verified Momentum Watchlists - Улправда
Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Update Summary & Expert Curated Trade Setup Alerts - ulpravda.ru
Market Moves: Is Phathom Pharmaceuticals Inc. stock oversold or undervalued2025 Winners & Losers & Consistent Income Trade Ideas - ulpravda.ru
US Market Wrap: Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Phathom Pharmaceuticals Inc. stock oversold or undervaluedJuly 2025 Recap & Detailed Earnings Play Strategies - Улправда
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Earnings Recap: Can Phathom Pharmaceuticals Inc stock weather global recessionPortfolio Gains Report & Real-Time Stock Entry Alerts - moha.gov.vn
Phathom Pharmaceuticals Inc Stock Analysis and ForecastEarnings Miss Alerts & Affordable Portfolio Tips - earlytimes.in
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month HighWhat's Next? - MarketBeat
683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at $16.27 By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals stock hits 52-week high at $16.27 - Investing.com India
Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating - Investing.com Canada
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
(PHAT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Barclays Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target - marketscreener.com
Is WPIL Limited Still a Good Stock to Buy After Recent Earnings - earlytimes.in
Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year HighWhat's Next? - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD - Investing.com
Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in
How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union
Phathom Pharmaceuticals Inc. (PHAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
What Wall Street predicts for Phathom Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a contrarian buyGap Up & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 20252025 Top Decliners & Proven Capital Preservation Methods - newser.com
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
0.08%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):